trial

Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

NCTId NCT05838560
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Active Not Recruiting
Enrollment 40 (estimated)
Sponsored by Washington University School of Medicine
Primary completion 2027-10-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Active Not Recruiting
Enrollment
40 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2023-07-01
Primary completion
2027-10-01
Eligibility
ALL · 50 Years

Interventions & indications

Drugs
Dasatinibquercetin

Sponsors

Washington University School of MedicineLead Sponsor
UConn HealthCollaborator

Investigators

1
Eric Lenze, MDPrincipal Investigator

Sites

1 total
St Louis, United States

Linked catalysts

1
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders — primary completion2027-10-01

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE2
Primary Completion Date
2027-10-01
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
drug
Dasatinib
drug
quercetin
drug
lead_sponsor
Washington University School of Medicine
company
collaborator
UConn Health
company
indication
Aging, Premature
indication
Depressive Disorder, Treatment-Resistant
indication
Schizophrenia
indication
investigator
Eric Lenze, MD
person